These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22382879)

  • 1. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
    Asahina H; Tamura Y; Nokihara H; Yamamoto N; Seki Y; Shibata T; Goto Y; Tanioka M; Yamada Y; Coates A; Chiu YL; Li X; Pradhan R; Ansell PJ; McKeegan EM; McKee MD; Carlson DM; Tamura T
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1477-86. PubMed ID: 22382879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
    Xiong H; Chiu YL; Ricker JL; LoRusso P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):55-61. PubMed ID: 24810181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
    Chiu YL; Carlson DM; Pradhan RS; Ricker JL
    Clin Ther; 2013 Nov; 35(11):1770-7. PubMed ID: 24094464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Horinouchi H; Yamamoto N; Nokihara H; Horai T; Nishio M; Ohyanagi F; Horiike A; Nakagawa K; Terashima M; Okabe T; Kaneda H; McKee MD; Carlson DM; Xiong H; Tamura T
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):37-43. PubMed ID: 24807459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
    J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
    Salem AH; Koenig D; Carlson D
    Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
    Tan EH; Goss GD; Salgia R; Besse B; Gandara DR; Hanna NH; Yang JC; Thertulien R; Wertheim M; Mazieres J; Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci FA; Ricker JL; Carlson DM; Soo RA
    J Thorac Oncol; 2011 Aug; 6(8):1418-25. PubMed ID: 21597387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
    Wong CI; Koh TS; Soo R; Hartono S; Thng CH; McKeegan E; Yong WP; Chen CS; Lee SC; Wong J; Lim R; Sukri N; Lim SE; Ong AB; Steinberg J; Gupta N; Pradhan R; Humerickhouse R; Goh BC
    J Clin Oncol; 2009 Oct; 27(28):4718-26. PubMed ID: 19720910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
    Toh HC; Chen PJ; Carr BI; Knox JJ; Gill S; Ansell P; McKeegan EM; Dowell B; Pedersen M; Qin Q; Qian J; Scappaticci FA; Ricker JL; Carlson DM; Yong WP
    Cancer; 2013 Jan; 119(2):380-7. PubMed ID: 22833179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
    Tannir NM; Wong YN; Kollmannsberger CK; Ernstoff MS; Perry DJ; Appleman LJ; Posadas EM; Cho D; Choueiri TK; Coates A; Gupta N; Pradhan R; Qian J; Chen J; Scappaticci FA; Ricker JL; Carlson DM; Michaelson MD
    Eur J Cancer; 2011 Dec; 47(18):2706-14. PubMed ID: 22078932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.
    Chan E; Goff LW; Cardin DB; Ancell K; Smith SJ; Whisenant JG; Ye F; Berlin JD
    Invest New Drugs; 2017 Aug; 35(4):491-498. PubMed ID: 28353122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.
    Chiu YL; Lorusso P; Hosmane B; Ricker JL; Awni W; Carlson DM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):213-7. PubMed ID: 24241212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
    Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linifanib: current status and future potential in cancer therapy.
    Aversa C; Leone F; Zucchini G; Serini G; Geuna E; Milani A; Valdembri D; Martinello R; Montemurro F
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):677-87. PubMed ID: 25936222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Honda K; Tamura Y; Wakui H; Sasaki T; Yusa W; Fujino K; Tamura T
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1153-61. PubMed ID: 26530955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.